Novel nucleocapsid protein-targeting phenanthridine inhibitors of SARS-CoV-2.
Eur J Med Chem
; 227: 113966, 2022 Jan 05.
Article
in English
| MEDLINE | ID: covidwho-1487705
ABSTRACT
The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unprecedented in human history. As a major structural protein, nucleocapsid protein (NPro) is critical to the replication of SARS-CoV-2. In this work, 17 NPro-targeting phenanthridine derivatives were rationally designed and synthesized, based on the crystal structure of NPro. Most of these compounds can interact with SARS-CoV-2 NPro tightly and inhibit the replication of SARS-CoV-2 in vitro. Compounds 12 and 16 exhibited the most potent anti-viral activities with 50% effective concentration values of 3.69 and 2.18 µM, respectively. Furthermore, site-directed mutagenesis of NPro and Surface Plasmon Resonance (SPR) assays revealed that 12 and 16 target N-terminal domain (NTD) of NPro by binding to Tyr109. This work found two potent anti-SARS-CoV-2 bioactive compounds and also indicated that SARS-CoV-2 NPro-NTD can be a target for new anti-virus agents.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Phenanthridines
/
Coronavirus Nucleocapsid Proteins
/
SARS-CoV-2
Type of study:
Prognostic study
Limits:
Animals
/
Humans
Language:
English
Journal:
Eur J Med Chem
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS